The UK is behind most first world countries in routinely using bevacizumab or biosimilars to treat many cancers. Recent 2019 evidence shows that survival rates are better for MCRC patients using this treatment alongside chemotherapy.
You may be interested in these active petitions
People may be dying unnecessarily due to this drug not being available.
We believe the Government should review the decision not to make bevacizumab and biosimilars routinely available for the treatment of certain cancers to take into account changes in the medical understanding of Metastatic Colorectal Cancer in particular and the use of targeted (EGFR) therapies.